AQST (18) PHAT (34) INDP (44) DMAC (44) ⌘ Pro Terminal →

Oculis Holding AG (OCS) — RQD Stock Rating Cockpit

$8.26 +0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.25

Oculis Holding AG (OCS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $507.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OCS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Oculis Holding AG (NASDAQ: OCS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.26 (+0.24% 1D, market cap $507.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OCS ranks #344 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OCS compare to AQST and PHAT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OCS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AQST (Aquestive Therapeutics Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $507.1M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $503.2M). Among the 5-stock peer group, OCS leads on earnings multiple (N/A) while AQST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OCS?

▼

For Oculis Holding AG (OCS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #344 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.25 (-0.15%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OCS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY OCS SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($14.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$7.88-7.1% Next Q

Q2 (-2Q)

Grade D$7.32+8.7% Next Q

Q3 (-1Q)

Grade D$7.96+3.8% Next Q

Current

Grade D$8.26-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OCS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OCS currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.65) and Max Pain ($8.67) forces dealer call-delta covering toward $36.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OCS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OCS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

45.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $7$8.26H: $34

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on OCS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like OCS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OCS)

✓Walkthrough of OCS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OCS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.77%🛡️ HOLDING TREND SUPPORT

2026-11-02O $7.98H $8.26L $7.98C $8.26VOL 263.7K

RES: $12.64SUP: $6.22SMA50: $9.65SMA200: $18.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OCS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OCS Butterfly Map → + Track OCS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OCS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OCS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OCS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OCS)

Health Care Rank #344 of 1016 ⚔️ AQST vs OCS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OCS vs. AQST, PHAT, INDP, DMAC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Oculis Holding AG (OCS) ranks #344 by composite RQD confidence (47/100, grade D) and #448 by equity capitalization ($507.5M). Within this direct 5-issuer industry benchmark cohort, OCS leads on earnings valuation at N/A trailing P/E, while AQST leads on capital efficiency and profitability with -35.0% ROIC and 58.3% gross margin. OCS currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OCS ACTIVE Oculis Holding AG	D	47/100	—	—	—	+0.24%	$507.5M	Benchmark Subject
AQST Aquestive Therapeutics Inc.	E	18/100	—	58.3%	-35.0%	-3.71%	$507.1M	/aqst-vs-ocs →
PHAT Phathom Pharmaceuticals Inc.	E	34/100	—	87.1%	-35.0%	-7.72%	$503.2M	/phat-vs-ocs →
INDP Indaptus Therapeutics Inc.	D	44/100	—	—	-35.0%	-7.48%	$513.0M	/indp-vs-ocs →
DMAC DiaMedica Therapeutics Inc.	D	44/100	—	—	-35.0%	-2.84%	$513.4M	/dmac-vs-ocs →

2. OCS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Oculis Holding AG (OCS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $507.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. OCS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OCS compare to AQST and PHAT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OCS?

Where is OCS trading relative to its 50-day, 200-day, and 52-week technical levels?

OCS last traded at $8.26 (+0.24% on volume of 309,711 shares), positioning the stock -14.40% below its 50-day simple moving average ($9.65) and -55.92% below its 200-day simple moving average ($18.74). Across its 52-week range of $7.11 to $34.47, OCS sits at the 4.2% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.23 to $9.29).

OCS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell OCS stock right now?

Oculis Holding AG (OCS) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is OCS's 12-month price target and RQD AI Jury consensus?

OCS's 12-month base price target is $7.85 (range $6.12 to $36.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: OCS RQD Cockpit OCS 12M Forecast OCS Earnings & Move OCS Dividends & DRIP OCS Insiders & 13F OCS Whale Options OCS Profit Sankey OCS News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

OCS — Oculis Holding AG: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:15:50Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, OCS scores 47 out of 100, a D grade, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 5/20 (institutional accumulation and options positioning); Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are Whale 13F Flow and Macro Regime Fit, while the balance sheet is the strongest. The cash-generation pillar is weak because the source reports zero ROIC and zero FCF yield, meaning the rating provides no evidence of current cash-based return to shareholders. The balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) are the main reason the score is not lower, which suggests financial solvency is less of a concern than the lack of earnings power and the institutional and insider signals. The rating label itself flags distribution risk. Upside drivers would need to come from outside the scored factors; the source data does not identify any.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or bottlenecks are identified in the source data. Sector classification is Health Care and industry is Biotechnology: Pharmaceutical Preparations. Beyond this classification, no ripple effects can be drawn from the source.

Open Questions

What are the company's revenue, operating income, and net income for recent reported periods, given that the financials section is empty?
Why does the market data show 0% gross, operating, and net margins, and is this a pre-revenue or early-commercial stage?
What drives the 52-week range of $7.11 to $34.47, and what news or events account for the price movement?
Who are the institutional holders and insiders behind the whale and insider pillar scores, and what are the direction and size of their trades?
What is the consensus analyst rating and price target, and does the 0% dividend yield reflect a policy of reinvestment?

OCS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oculis Holding AG (OCS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OCS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 15h ago

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 4d ago

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyondZUG, Switzerland, October 29th, 2026 -- Oculis Holdi

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 10d ago

HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

Read Full Source ↗

🔴 RISK WATCH Benzinga • 11d ago

Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 13d ago

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 14d ago

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: L

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OCS Bull vs. Bear Conversation Board — What's Your Call at $8.26?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OCS 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $8.90 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is OCS (D • RQD 47/100) a Buy at $8.24?

Welcome to the OCS (Oculis Holding AG) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.34 (-23.1%)

Spot @ $8.24

Pump the brakes on OCS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on OCS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Oculis Holding AG expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.38 (+26.0%)

Spot @ $8.24

OCS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on OCS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.24 (52-wk range $7.11 - $34.47), any beat on forward guidance forces shorts and underweight funds to chase.